author-photo

Murat O. Arcasoy

Duke University

110

Papers

5401

Citations

Citation Trend

Filter By

Papers (77) Sort By

Journal Conference Others

Safety and Efficacy of Ruxolitinib in Patients With Myelofibrosis and Low Platelet Counts (50–100 × 109/L): Final Analysis of an Open-label Phase 2 study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions.

2021 Advances in radiation oncology
Show All
- Source
- Cite
- Save
Citations (1)
Arterial thrombosis and second cancer in MPNs

2020 Blood
- Murat O. Arcasoy
Show All
- Source
- Cite
- Save
Citations (1)
Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A novel nucleotide substitution in the 5′ untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families

2019 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (2)
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

2019 Blood
Show All
- Source
- Cite
- Save
Citations (4)
ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation

2019 Genes & Development
Show All
- Source
- Cite
- Save
Citations (39)
Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

2018 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (33)
Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)